ストックスクリーナーアプリを入手
2.25
2.72%
0.05
前日終値:
$2.20
開ける：
$2.24
24時間の取引高:
115.26K
Relative Volume:
0.20
時価総額：
$138.08M
収益：
$139.77M
当期純損益:
$-97.62M
株価収益率:
-1.4241
EPS:
-1.58
ネットキャッシュフロー:
$-61.71M
1週間 パフォーマンス:
-0.44%
1か月 パフォーマンス:
-11.72%
6か月 パフォーマンス:
-38.92%
1年 パフォーマンス:
-85.93%
1日の値動き範囲:
$2.185
$2.27
1週間の範囲:
$2.16
$2.485
52週間の値動き範囲:
$2.16
$19.54
Macrogenics Inc Stock (MGNX) Company Profile
名前
Macrogenics Inc
セクター
電話
301-251-5172
住所
9704 MEDICAL CENTER DRIVE, Rockville, MD
MGNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.25 | 138.08M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
670.18 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.60 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-07 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-07-31 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-05-10 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | ダウングレード | Stifel | Buy → Hold |
| 2024-05-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-04-26 | 開始されました | B. Riley Securities | Buy |
| 2024-04-09 | アップグレード | TD Cowen | Hold → Buy |
| 2024-03-04 | 繰り返されました | BTIG Research | Buy |
| 2024-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-11-22 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-11-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-02-28 | アップグレード | Citigroup | Neutral → Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-04 | 開始されました | SMBC Nikko | Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-12 | アップグレード | Barclays | Underweight → Overweight |
| 2020-12-22 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-06-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2019-12-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-11-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Guggenheim | Neutral |
| 2019-02-07 | アップグレード | Citigroup | Sell → Buy |
| 2019-02-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-02-06 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-12-10 | ダウングレード | Raymond James | Outperform → Underperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-05-31 | 開始されました | Evercore ISI | Outperform |
| 2018-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-31 | 開始されました | Raymond James | Outperform |
すべてを表示
Macrogenics Inc (MGNX) 最新ニュース
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com
MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com
MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call - GlobeNewswire
MacroGenics at TD Cowen Conference: Strategic Innovations in Immunotherapy - Investing.com India
MacroGenics, Inc. to Announce 2024 Financial Results on March 20, 2025 - Nasdaq
MacroGenics Earnings: Will Q4 Results Reveal Biotech's Growth Trajectory? - StockTitan
MacroGenics Inc earnings beat by $0.33, revenue topped estimates - Investing.com Australia
MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire
Three Companies Surpass Quarterly Earnings Expectations - Evrim Ağacı
Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: - openPR
Investors Who Lost Money on MacroGenics, Inc. (MGNX) Should Contact Levi & Korsinsky About Pending Class ActionMGNX - ACCESS Newswire
Macrogenics Stock Hits 52-Week Low at $2.31 Amid Sharp Decline - Investing.com India
MacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
Macrogenics Stock Hits 52-Week Low at $2.31 Amid Sharp Decline By Investing.com - Investing.com South Africa
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsMGNX - ACCESS Newswire
MACROGENICS Earnings Preview: Recent $MGNX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics, Inc. (MGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Shareholders that lost money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Sept. 24th Deadline Alert: Investors Who Lost More Than $100,000 With MacroGenics, Inc. (NASDAQ:MGNX) Shares Should Contact the Shareholders Foundation - ACCESS Newswire
MacroGenics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by MacroGenics, Inc. (MGNX) - ACCESS Newswire
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsMGNX - ACCESS Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate MacroGenics, Inc. (MGNX) Regarding Possible Securities Fraud Violations - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26% - Simply Wall St
Lost Money on MacroGenics, Inc. (MGNX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMGNX - ACCESS Newswire
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far - Seeking Alpha
MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire
How Will MacroGenics Address Investors at Three Key Healthcare Conferences? - StockTitan
MacroGenics CEO departure date extended amid search for successor By Investing.com - Investing.com Australia
MacroGenics (MGNX) to Release Earnings on Thursday - Defense World
Shareholders of MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX - ACCESS Newswire
MacroGenics CEO departure date extended amid search for successor - Investing.com
MacroGenics Extends CEO’s Separation Agreement - TipRanks
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MacroGenics, Inc. to Contact the Firm Today! - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on MacroGenics, Inc.(MGNX) should contact Levi & Korsinsky about pending Class ActionMGNX - ACCESS Newswire
Shareholders that Lost Money on MacroGenics, Inc. (MGNX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investor Network: MacroGenics, Inc. to Host Earnings Call - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsMGNX - ACCESS Newswire
Macrogenics VP Beth Smith sells $1,082 in common stock - Investing.com India
Macrogenics VP Beth Smith sells $1,082 in common stock By Investing.com - Investing.com South Africa
Macrogenics Inc (MGNX) 財務データ
収益
当期純利益
現金流量
EPS
Macrogenics Inc (MGNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
| SIEGEL JAY PHILIP | Director |
May 20 '24 |
Option Exercise |
0.00 |
4,500 |
0 |
4,500 |
1.28%
0.80%
大文字化:
|
ボリューム (24 時間):